niacinamide has been researched along with Carcinoma, Mucoepidermoid in 3 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
Carcinoma, Mucoepidermoid: A tumor of both low- and high-grade malignancy. The low-grade grow slowly, appear in any age group, and are readily cured by excision. The high-grade behave aggressively, widely infiltrate the salivary gland and produce lymph node and distant metastases. Mucoepidermoid carcinomas account for about 21% of the malignant tumors of the parotid gland and 10% of the sublingual gland. They are the most common malignant tumor of the parotid. (From DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p575; Holland et al., Cancer Medicine, 3d ed, p1240)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Sorafenib is the first anti-angiogenic agent to demonstrate activity in RMSGC patients, particularly in some histotypes such as HG-MEC, SDC and adenocarcinoma, NOS." | 5.22 | A phase II study of sorafenib in recurrent and/or metastatic salivary gland carcinomas: Translational analyses and clinical impact. ( Alfieri, S; Bergamini, C; Bossi, P; Civelli, E; Cortelazzi, B; Dagrada, GP; Granata, R; Imbimbo, M; Licitra, L; Lo Vullo, S; Locati, LD; Mariani, L; Mirabile, A; Morosi, C; Orlandi, E; Perrone, F; Pilotti, S; Quattrone, P; Resteghini, C; Saibene, G, 2016) |
| " It is our conclusion that radiotherapy combined with carbogen and nicotinamide is a safe treatment with manageable side effects." | 1.29 | Radiotherapy with carbogen breathing and nicotinamide in head and neck cancer: feasibility and toxicity. ( Kaanders, JH; Marres, HA; Pop, LA; van Daal, WA; van der Kogel, AJ; van der Maazen, RW, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yu, HJ | 1 |
| Shin, JA | 1 |
| Jung, JY | 1 |
| Nam, JS | 1 |
| Hong, IS | 1 |
| Cho, NP | 1 |
| Cho, SD | 1 |
| Locati, LD | 1 |
| Perrone, F | 1 |
| Cortelazzi, B | 1 |
| Bergamini, C | 1 |
| Bossi, P | 1 |
| Civelli, E | 1 |
| Morosi, C | 1 |
| Lo Vullo, S | 1 |
| Imbimbo, M | 1 |
| Quattrone, P | 1 |
| Dagrada, GP | 1 |
| Granata, R | 1 |
| Resteghini, C | 1 |
| Mirabile, A | 1 |
| Alfieri, S | 1 |
| Orlandi, E | 1 |
| Mariani, L | 1 |
| Saibene, G | 1 |
| Pilotti, S | 1 |
| Licitra, L | 1 |
| Kaanders, JH | 1 |
| Pop, LA | 1 |
| Marres, HA | 1 |
| van der Maazen, RW | 1 |
| van der Kogel, AJ | 1 |
| van Daal, WA | 1 |
1 trial available for niacinamide and Carcinoma, Mucoepidermoid
| Article | Year |
|---|---|
A phase II study of sorafenib in recurrent and/or metastatic salivary gland carcinomas: Translational analyses and clinical impact.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma, Adenoid Cystic; Carcinoma, Mucoepider | 2016 |
2 other studies available for niacinamide and Carcinoma, Mucoepidermoid
| Article | Year |
|---|---|
Inhibition of myeloid cell leukemia-1: Association with sorafenib-induced apoptosis in human mucoepidermoid carcinoma cells and tumor xenograft.
Topics: Animals; Apoptosis; Blotting, Western; Carcinoma, Mucoepidermoid; Cell Proliferation; Disease Models | 2015 |
Radiotherapy with carbogen breathing and nicotinamide in head and neck cancer: feasibility and toxicity.
Topics: Administration, Inhalation; Administration, Oral; Adult; Aged; Aged, 80 and over; Carbon Dioxide; Ca | 1995 |